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Abstract
Background and study objectives: Blood transfusion is central in the prevention and treatment of certain chronic
complications of sickle cell disease. It is indispensible in correcting anaemias as well as in the practice of exchange
blood transfusion. These gains are largely limited by formation of allo-antibodies. Several studies demonstrated
varying frequencies of allo-immunization in various patient groups. The effect of the racial differences between the
donor and recipient pool, which has been subsumed in this study, has continuously created a confounding effect
on the results of previous studies.
Aim: This study was aimed at determining the pattern and frequency of allo-immunization in multiply transfused
sickle cell patients, in a racially matched donor and recipient population.
Patients and methods: This was a cross-sectional case-controlled study involving 80 Nigerian sickle cell disease
patients who had received three or more units of packed red cells in the within 4 weeks of the study and 40
controls (who were SCD that had not been transfused in their life time). Antibody screening and identification was
done using the Diamed microtyping system.
Results: Frequency of allo-immunization was determined to be 18.7 % (15/80) among the previously transfused
and 5 % (15/120) in all sickle cell disease patients. Auto-antibodies were detected in 1.25 % of the study group and
2.5 % of the control, and all reacted with the Kell and Lutheran blood group antigens. The pattern of allo-antibodies
found showed; 46.7 % Rhesus, 40 % Kell, while Lutheran and Duffy 13.3 %, each.
Conclusion: Sickle cell disease patients are particularly susceptible to development of allo-antibodies despite racial
similarities between the donor and recipient population. The most common allo-antibodies are Rhesus, Kell and
Lutheran and Duffy respectively in order of decreasing frequency. Development of auto-antibodies seems to be
independent of blood transfusion in sickle cell disease with possibly different pathogenetic mechanism. Policy on
extended red cell phenotyping for common antigens will reduce allo-immunization among multiply transfused
patients.
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Background
Sickle cell disease (SCD) is an inherited qualitative abnor-
mality of haemoglobin and the most frequently occurring
genetic disease afflicting mankind [1–5]. This condition
has the highest prevalence in the Equatorial region of
Africa, though the gene has a widespread distribution, af-
fecting people of European, Arabian, Indian and Oriental
ancestry [1, 3]. About 300,000 children are born annually
with SCD woridwide [1], of which 100,000 are born to
Nigerian parents. Millions of people are affected worldwide,
making it a major public health problem on a global scale.
Sickling of red blood cells, vaso-occlusion and suscep-
tibility to infections are the hallmark of the pathological
processes in SCD. Risk factors for sickling include hyp-
oxia, acidosis and rise in temperature, stress and hyper-
osmolality. Background haemolysis of the sickle red cells
lead to marrow hyperplasia with consequent anaemia.
This is further worsened by any superimposed stress on
erythropoiesis; like malaria, bacterial infections and
acute sequestration, thus necessitating transfusion.
Medical management includes a wide range of treat-
ment modalities ranging from vaccination against capsu-
lated organisms, use of antibiotics to treat infections,
analgesics to treat painful episodes, fluid administration to
correct and prevent dehydration, regular folic acid supple-
mentation, prophylactic anti-malarial and blood transfu-
sion among others [1]. Transfusion of red blood cells
(RBCs) is a common practice in the treatment of patients
with sickle cell disease (SCD) such that most adult
patients with SCD have been transfused at one time or
another, many with large number of units of blood.
Red cell transfusion is usually not required in steady
state patients but blood transfusion remains the mainstay
therapy for many of the complications of SCD [6–8], how-
ever it is associated with complications such as iron over-
load, transfusion transmitted infections, acute lung injury,
anaphylaxis, and allo-immunization [7–9]. The frequency
of development of allo-antibodies in transfused patients
with sickle cell disease has been studied in many parts of
the world and the risk of development of red cell allo-
immunization also has been found to be high with overall
incidence ranging from 18 to 36 % [1, 10–13].
Sixty six percent of the allo-antibodies identified in
most of the reports were those of the Rhesus (Rh) and
Kell systems in SCD [1, 11, 14–16]. Some studies identi-
fied allo-antibodies of the Kidd and Duffy systems in
addition to the Rh and Kell systems. Several studies have
also confirmed that matching for major Rh and Kell
antigens prevent formation of allo-antibodies in 53.3 %
of patients and further extended typing to include MNS,
Duffy (Fya) and Kidd blood groups will prevent allo-
immunization in 70.8 % of patients [1, 14, 17, 18]. This
leaves at least one-third of the allo-antibodies formation
still unaccounted for. These previous studies were also
done without taking cognizance of the racial disparity
between donors and recipients, a factor which definitely
impacts on the propensity to form allo-antibodies.
The purpose of this study therefore, is to characterize
the allo-antibodies formed with racially matched blood
given to multiply transfused (more than two units) pa-
tients with sickle cell disease. This would effectively check
the confounding effect of the racial differences in distribu-
tion of red cell antigens. It also aims to ascertain the
prevalence of allo-immunization and evaluate the specifi-
city as well as the clinical relevance of the allo-antibodies
found.
Patients and methods
This was a prospective cross-sectional study carried out
at the adult and paediatric sickle cell clinics of the
University of Nigeria Teaching Hospital Ituku Ozalla,
Enugu Nigeria.
Patients recruitment
One hundred and twenty patients from both adults and
paediatric sickle cell clinic who gave written informed
consent were recruited for the study. In the case of paedi-
atric patients, informed consent was obtained from their
parents or guardian. A standard questionnaire was com-
pleted by the patient (or their care givers, in the case of
minors) during the recruitment process before entry into
the study. They were divided into two groups according
transfusion history obtained from a questionnaire.
Data collection
Group 1 (Study Group) subjects were 80 previously di-
agnosed SCD patients who had received more than two
units of red cells transfusion in their life time and the
last unit of blood received was more than 4 weeks prior
to sample collection. The sample size of 80 for the study
group was obtained using GraphPad Statmate 2.0, preva-
lence rate of sickle cell anaemia in Nigeria being noted
to be 0.026 in previous studies.
Group 2 (Control Group) subjects were 40 SCD pa-
tients who had never been transfused as determined by
history and review of case notes.
Antibody screening was carried with Diamed Micro-
typing System, using a 6-well gel card each containing
low ionic saline solution (LISS/ coombs card). 50 μl of
the commercially prepared Diacels I, II, and III, was
added into corresponding wells for the test, 25 μL of the
test plasma was added into each of the 6 wells. 50 μL of
the patients cell suspension was added into the commer-
cially prepared cells from Diamed well of auto control.
Diacells I and II were added into the last two wells con-
taining enzymes. The gel card was incubated for 15 min
using Diamed incubator, at 37 °C and then centrifuged for
10 min at 1000p/min using Diamed centrifuge. The
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results were read both visually and by the use of comput-
erized ID – reader of the Diamed- cooperation. The cells
that are agglutinated (positive reaction) remained trapped
in the gel while those that are not agglutinated (negative
reaction) passed through the beads of the gel to the bot-
tom of the well.
Ethical approval was obtained from the University of
Nigeria Teaching Hospital Health Research and Ethics
review committee.
Statistics
The relationship between the age of the patients and the
presence of antibodies (allo, auto or both was calculated
using the Pearsons and Kendaull tau_b correlation coef-
ficient. Significance was set at all values less 0.05. While
the relationship between the sex of the patients and the
presence of antibodies ws calculated using the Chi Square
and Fischers exact test. The Statistical Package for Social
Sciences (SPSS) version 17.0 (Chicago IL) was used for
data analysis and the results obtained were expressed in
figures and tables.
Results
Antibody screening was carried out on 120 SCD pa-
tients, divided into the study and control group. The pa-
tients were aged 1–50 years with a median age of
21 years. Eighty of the patients had been transfused in
the past while 40 of them had not been previously trans-
fused. In all, there were 59 males and 61 females, while
among the 80 previously transfused patients, there were
35 males and 45 females. Of those transfused, 44.2 %
had their last transfusion more than a month ago and
their median age as at the first transfusion was 8 years.
The age and sex distribution of the patients in this study
are shown on Fig. 1a.
The prevalence of allo-immunization among sickle cell
patients was determined to be 5 % (15/120). There seemed
to be some relationship, though not statistically signifi-
cant, between increasing age and presence of antibodies
(p = 0.068). There was also no relationship observed be-
tween the sex of the patients and the development of anti-
bodies, Chi square value 0.033 (p = 0.855).
While the prevalence of allo-immunization amongst
the patients who had been previously transfused with ra-
cially matched blood was 18.7 % (15/80). The transfused
patients had received an average of 3 units of red cells in
the past. Nineteen (23.8 %) of the previously transfused
patients had experienced various forms of transfusion
reaction. There had also been difficulty in cross-
matching blood for 3 (3.8 %) of them, and there was no
association between the age or sex of patients in this
group and the occurrence of antibodies (p =0.519 and
0.264, respectively). The age and sex distribution of the
patients as well as the number of units of red cell s
transfused are shown in Fig. 1b.
Thirty of the patients, all from the study group had
anti-red cell antibodies (either auto-, allo- or both forms
of red cell antibodies). One patient had a solitary posi-
tive Coombs test, 15 patients had combined positive
Coombs (auto-antibodies) and red cell antigen tests
(allo-antibodies), 11 patients had positivity only for the
red cell antigen test, while 90 patients had double nega-
tive (absence of both auto and allo-antibodies) result. Of
the 30 patients that reacted with antibodies during
screening, only 15 allo-antibodies and 3 auto antibodies
were found. No allo-antibody was identified from the 11
patients that reacted positively with enzymes of gel cards
alone, these were false positives. There is increased fre-
quency of false positive results in the use of enzymes
alone in antibody screening, Table 1.
None of the patient in the control group had devel-
oped red cell allo-antibodies. Blood transfusion is signifi-
cantly associated with allo-immunization, P = 0.000. Of
the 3 auto-antibodies identified, one was from study
group and the other two were from control group. Anti-
body Identification of the 15 allo-antibodies found re-
vealed that, 7 (46.7 %) patients reacted positively to
Rhesus blood group system, 1 (6.7 %) specifically to D
antigen, 2 (13.3 %) to E antigen, 2 (13.3 %) to c antigen
and 2 (13.3 %) to e antigen. 2 (13.3 %) of the patients
reacted positively to Duffy blood group system, 1(6.7 %)
specifically to Fya antigens and 1 (6.7 %) to Fyb antigens.
6 (40 %) patients reacted positively to the combination
of k, kpb and Jsb antigens of the Kell blood group as well
as Lutheran (Lua) antigens of the Lutheran blood group,
Fig. 1c. All the auto antibodies reacted to Kell as well as
Lutheran antigens, Table 2.
Allo-antibodies were also found in all the patients who
developed auto-antibodies. Sixty one females were in-
volved in the study of which only three were married
and all the three had alloantibodies.
Discussion
Development of allo-immunization depends on number
factors such as racial difference between the donor
population and the recipient, number of blood units
transfused, age of the patient, severity of the disease and
Hb genotype among other things. This study provides
information on the prevalence of allo-immunization in a
racially identical donor-recipient population, thus ameli-
orating for the effects of antibodies formed as a result of
dono-recipient racial discrepancy.
In this study 18.7 % developed allo-immunization
among multiply transfused patients even though both
the donor and the recipients have similar racial back-
ground and none among non-transfuse patients. The
prevalence of allo-immunization in our study is slightly
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Fig. 1 a Distribution of age and types of antibodies detected in the transfused sickle cell patients. b Distribution of the total number of units of
blood and ages of patients amongst sickle cell anaemia patients. c Frequency of occurrence of the various types of antibodies observed in sickle
cell patients
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higher to prevalence in other studies done in Nigeria
8.8 % in Kano and 3.2 % in Lagos. This may be attrib-
uted to the sensitivity (automated gel technology) of the
method used in this study as opposed to manual visual
method used in other studies. The use of Coombs re-
agents with enzymes - papain and bromelin, which were
used in this study enhances reactivity of some antibodies
such as Rh, P, I, Kidd and Lewis, explaining the higher
detection rate of the antibodies as compared with other
studies. The results obtained using these reagents were;
12.5 %, using Coombs reagent with papain and bromelin,
compared to Coombs reagents only 0.8 % and enzymes
only 9.2 %, which implies a variation in reactivity.
Several international studies showed a wide variation
in frequencies of allo-immunization in sickle cell disease
such as 6.1 % in Uganda, 29 % in US, 21 % in UK, 30 %
in Oakland US, 12.0 and 41 % respectively in two separ-
ate reports from Brazil [19–22]. In general, the fre-
quency ranges between 18 and 36 % in most of the
studies [23]. Our data concur with the results of many
studies that allo-immunization occurs in multiply trans-
fused patient with sickle cell disease with the same racial
background between the donor and recipient population.
These findings further reaffirm previous observations
that multiple blood transfusion is associated with
development of alloimmunisation even in racially
matched donors and recipient.
The development of auto-antibodies seems to be inde-
pendent of allo-immunization or blood transfusion. In
this study auto-antibodies were detected in three per-
sons;, one in multiply transfused patients and two in
non transfused group. This further conforms to the find-
ings of other studies. Several studies have shown that D,
C/c, E/e, and K antigen matching decreases the risk of
alloimmunization [24, 25], Even with such phenotype
antigen matching, alloimmunization is still a major
problem. This suggests that the development of auto-
antibodies in sickle cell disease may be due to genetic re-
spondents with an increased tendency to develop
erythrocyte antibodies or due to exposure of neo-
antigens from repeated destruction of erythrocyte mem-
brane that induces IgG autoantibody formation.
Conclusion
Multiply transfused patient with sickle cell disease are
prone to development of allo-antibodies despite similar
racial background between the donor and recipient
population. The prevalence of allo-immunization amongst
multiply transfused sickle cell patients who received ra-
cially matched blood was found to be 18.7 %. Lack of ex-
tended red cell typing among multiply transfused patients
further predisposes to allo-immunization. The develop-
ment of auto antibodies appears to be independent of
blood transfusion in sickle cell disease patients. The age of
the patient and multiple blood transfusions are signifi-
cantly associated with the development of allo-
immunization, P = 0.000.
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Table 1 Frequency and pattern of agglutination in sickle cell patients
Antibody screening
Frequency Percent Valid % Cumulative %
Agglutination with Coombs reagent only 1 0.8 0.8 0.8
Agglutination with Coombs reagent + enzymes 15 12.5 12.5 13.3
Agglutination with enzyme only 11 9.2 9.2 22.5
Agglutination with auto cells 3 2.5 2.5 25.0
No agglutination 90 75.0 75.0 100.0
Total 120 100.0 100.0
Table 2 Frequency and pattern of allo-antibodies observed
Antibody reactions and types of antibody
Types of antibody











7 2 5 1 0 15
Agglutination with enzyme
only
0 0 0 9 0 9
Agglutination with auto
cells
0 0 0 0 1 1
No agglutination 0 0 0 54 0 54
Total 7 2 6 64 1 80
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